MD-Onco Pub Date : 2022-12-13 DOI: 10.17650/2782-3202-2022-2-4-22-26

A. Mudunov, B. G. Pkheshkhova, P. A. Zeynalova, A. Fedenko, A. Batsev, M. Pak

引用次数: 0

Primary cutaneous diffuse large B-cell lymphoma, leg type, in an 80-year-old female patient. Clinical case 原发性皮肤弥漫性大b细胞淋巴瘤，腿部型，80岁女性患者。临床病例

MD-Onco Pub Date : 2022-12-13 DOI: 10.17650/2782-3202-2022-2-4-34-40

Yu. E. Ryabukhina, F. М. Abbasbeyli, O. L. Timofeeva, P. A. Zeynalova, A. G. Zhukov

{"title":"Primary cutaneous diffuse large B-cell lymphoma, leg type, in an 80-year-old female patient. Clinical case","authors":"Yu. E. Ryabukhina, F. М. Abbasbeyli, O. L. Timofeeva, P. A. Zeynalova, A. G. Zhukov","doi":"10.17650/2782-3202-2022-2-4-34-40","DOIUrl":"https://doi.org/10.17650/2782-3202-2022-2-4-34-40","url":null,"abstract":"Primary cutaneous diffuse large B-cell lymphoma, leg type, is diagnosed in 20-25 % cases of all primary cutaneous B-cell lymphomas, primarily in elderly women (older than 70 years). The disease has aggressive recurrent progression and worse prognosis than other variants. The standard antitumor drug therapy are such regimens as R-CHOP and CHOP-like programs including anthracycline antibiotics. Use of these programs can be limited by the presence of cardiovascular and other concomitant disorders.Due to the limited variety of combinations of antitumor agents, low frequency of diagnosis of this immunomorphological variant of lymphoproliferative disease and absence of a single algorithm of drug therapy, every clinical case is interesting and informative.In the presented clinical case, an 80-year-old female patient with primary cutaneous diffuse large B-cell lymphoma, leg type, and concomitant pathology of the cardiovascular system underwent 2 courses of R-CVP regimen drug therapy without anthracyclines. A significant antitumor clinical effect was achieved in the form of complete tumor regression. Treatment was not accompanied by significant toxicity which allowed to complete therapy.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"108 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134288413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient noncompliance as the cause of skin toxicity in capecitabine therapy 卡培他滨治疗中引起皮肤毒性的患者不依从性

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-55-58

L. Kogoniya, K. E. Borisov, K. I. Ershova

引用次数: 0

Neoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case 新辅助免疫疗法治疗少转移局部晚期结肠癌。临床病例

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-21-27

A. Rasulov, J. Madyarov, A. E. Kulikov, Z. Rasulov, L. A. Shestakova, D. Chekini, E. K. Ibragimov, E. Puchkova, Yu. E. Lvova, R. A. Rasulov

引用次数: 0

Endoscopic techniques used in obturation of the bronchus by metastasis of leiomyosarcoma of the retrocecal space. Clinical observation 内窥镜技术用于支气管闭塞的转移的平滑肌肉瘤的后盲肠间隙。临床观察

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-43-46

I. N. Iurichev, V. Vereshchak

引用次数: 0

Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation D-Rd项目在一线治疗75岁女性多发性骨髓瘤高危细胞遗传学患者中的有效性临床观察

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-28-35

Yu. E. Ryabukhina, F. М. Abbasbeyli, P. A. Zeynalova, O. L. Timofeeva, N. Kupryshina, A. G. Zhukov

{"title":"Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation","authors":"Yu. E. Ryabukhina, F. М. Abbasbeyli, P. A. Zeynalova, O. L. Timofeeva, N. Kupryshina, A. G. Zhukov","doi":"10.17650/2782-3202-2022-2-3-28-35","DOIUrl":"https://doi.org/10.17650/2782-3202-2022-2-3-28-35","url":null,"abstract":"Multiple myeloma is a B-cell lymphoproliferative disorder. Morphological substrate of the disorder are plasma cells producing monoclonal immunoglobulin, and the disorder is characterized by heterogeneity of clinical manifestations. Due to the understanding of molecular and biological basics of multiple myeloma pathogenesis, significant success was achieved in treatment of the standard and high-risk cytogenetics groups including full remission. However, not all patients show long-term progression-free survival. Necessity of more accurate evaluation of the extent of antitumor response, prognosis of progression-free survival and recurrence development led to minimal residual disease (MRD) testing. The analysis is based on detection of phenotypically aberrant clonal plasma cells in bone marrow aspirate after drug treatment. Currently, MRD-negative status is a significant prognostic factor. In some studies, high effectiveness of daratumumab in achievement of MRD-negative status in elderly patients with newly diagnosed multiple myeloma was demonstrated.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131009958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical observation of a 64-year-old female patient with plasma cell leukemia diagnosed during coronavirus infection COVID-19 1例64岁女性冠状病毒感染时诊断为浆细胞白血病的临床观察

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-47-54

Yu. E. Ryabukhina, O. L. Timofeeva, P. A. Zeynalova, F. М. Abbasbeyli, M. V. Antonets, V. E. Gruzdev, M. A. Anisimov, A. A. Akhobekov, N. Kupryshina

引用次数: 0

CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case CDK4/6抑制剂联合激素治疗的临床应用临床病例

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-36-42

D. Chekini, P. A. Zeynalova, E. K. Ibragimov, A. Y. Kolesnik, A. Fedenko

引用次数: 0

Successful combination treatment of metastatic ductal carcinoma of the pancreas tail pT4N0M1(per). Clinical case 胰腺尾部转移性导管癌pT4N0M1成功联合治疗(per)。临床病例

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-16-20

E. Glukhov, M. M. Davydov, A. Ivanov, A. A. Filatov, M. Shogenov, E. V. Dementieva

引用次数: 0

Possibilities of using statins in comprehensive antitumor treatment 他汀类药物在综合抗肿瘤治疗中的可能性

MD-Onco Pub Date : 2022-10-13 DOI: 10.17650/2782-3202-2022-2-3-59-64

R. Mustafin

{"title":"Possibilities of using statins in comprehensive antitumor treatment","authors":"R. Mustafin","doi":"10.17650/2782-3202-2022-2-3-59-64","DOIUrl":"https://doi.org/10.17650/2782-3202-2022-2-3-59-64","url":null,"abstract":"Frequency of atherosclerosis significantly increases with age, same as malignant tumor morbidity. Concurrent pathology (including in the cardiovascular system) affects selection of antitumor treatment limiting use of cardiotoxic (though highly effective) drugs. Statins are the main treatment for atherosclerosis but their study showed that regulation of cholesterol metabolism affects functioning of tumor cells. According to the results of clinical trial meta-analyses, regular use of statins decreases mortality in patients with bladder, prostate, renal, ovarian, lung, breast, and colorectal cancer both due to decreased risk of cardiovascular complications and increased effectiveness of antitumor drugs. In some studies, decreased risk of liver, esophageal, endometrial, renal, gastric, and pancreatic cancers was observed in patients taking statins. Antitumor effects of statins are supposedly mediated by decreased cholesterol production which is used by tumor cells for functioning and membrane synthesis. Additionally, statins inactivate RAS and RHO oncogenes by suppressing their isoprenylation, inhibit proliferation of tumor cells. Statins also contribute to activation of antitumor immunity, increased ferroptosis and autophagy. Statins activate apoptosis by interacting with mitochondrial procaspase 9, inhibit expression of toll-like receptors (TLR4), NF-κB, tumor necrosis factor α, interleukins 1β and 6, suppress the mTOR pathway. Therefore, multifaceted direct and indirect antitumor effects of statins show that these pharmaceuticals should be more intently considered as a component of antitumor therapy.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"190 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132958006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MD-Onco最新文献